Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mycophenolate mofetil (Cellcept).

M Behrend1

  • 1Abteilung für Abdominal- und Transplantationschirurgie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30623 Hannover, Germany.

Expert Opinion on Investigational Drugs
|July 5, 2005
PubMed
Summary

Mycophenolate mofetil (MMF), an immunosuppressant, effectively prevents renal allograft rejection by inhibiting lymphocyte proliferation. Clinical trials show MMF significantly reduces rejection rates with manageable side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A modified Whipple operation for carcinoma at the ampulla of Vater.

American journal of surgery·2010
Same author

Phlebitis, embolism and thrombosis.

The Journal of the International College of Surgeons·2010
Same author

Surgery of the common bile duct.

The Journal of the International College of Surgeons·2010
Same author

Common bile duct; anatomy, physiology and surgery.

The Journal of the International College of Surgeons·2010
Same author

Acute and chronic pancreatitis.

Postgraduate medicine·2010
Same author

Surgery of splenic tumors.

The Journal of the International College of Surgeons·2010

Area of Science:

  • Immunopharmacology
  • Transplantation immunology
  • Purine metabolism

Background:

  • Mycophenolate mofetil (MMF) is an immunosuppressive agent targeting inosine monophosphate dehydrogenase (IMPDH).
  • IMPDH is vital for purine synthesis in lymphocytes, crucial for T- and B-cell proliferation.
  • MMF's mechanism offers selective lymphocyte suppression.

Purpose of the Study:

  • To evaluate the efficacy and safety of MMF in preventing acute renal allograft rejection.
  • To compare MMF combined with standard immunosuppression against existing protocols.

Main Methods:

  • Three randomized, double-blind, multicenter trials involving nearly 1500 patients.
  • MMF was added to standard immunosuppressive regimens for renal transplant recipients.
  • Outcomes assessed included biopsy-proven acute rejection rates at six months.

Main Results:

  • MMF significantly reduced the incidence of biopsy-proven acute renal allograft rejection.
  • The adverse event profile was comparable to azathioprine-based triple therapy, with gastrointestinal, hematopoietic, and opportunistic infection risks.
  • Rapid and complete oral absorption of MMF was observed.

Conclusions:

  • MMF is an effective immunosuppressant for preventing acute renal allograft rejection.
  • It represents an improvement in immunosuppressive therapy for solid organ transplantation.
  • MMF is widely licensed globally for renal transplant recipients.

Related Experiment Videos